Contract award record
Oncotype DX Breast Cancer Testing
Notice details
- Published
- Category
- services
- Buyer region
- South East
- Source
- View official notice
Public buyer and contract winner
Award value£272,700
- AwardedCompleted
- StartCurrent phase
- EndUpcoming
Work description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.
Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.